Ruitao Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruitao Lin has a total of 372 co-authors. Here are the top co-authors by number of shared publications:
- Ying Yuan
The University of Texas MD Anderson Cancer Center, Houston, TX
46 shared publications - J. Jack. Lee
Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, TX
23 shared publications - Clifton David Fuller
Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
15 shared publications - Alex Koong
Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
12 shared publications - Alexander D. Sherry
Department of Radiation Oncology, Mayo Clinic, Rochester, MN
12 shared publications - Charles R. Thomas
Department of Radiation Oncology and Applied Sciences, Dartmouth Cancer Center, Geisel School of Medicine, Lebanon, New Hampshire. 8
12 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Wiley in Precision Radiation Oncology
Evaluation of Concordance between Radiation Therapists and Medical Physicists in MR‐Guided Online Adaptive Planning
Purpose: Magnetic resonance (MR) ‐guided online adaptive radiotherapy requires skill in online adaptive treatment planning. The aim of this study was to demonstrate that radiation therapists, with appropriate training, can consistently produce high‐quality adaptive plans concordant with those created by medical physicists for treatment on a 1.5 Tesla MR‐Linac (MRL). Methods: We evaluated plans generated by two experienced MRL radiation therapists and two MR‐Linac medical physicists using an adapt‐to‐position (ATP) workflow to treat 10 patients with head and neck cancer; this workflow includes an iso‐center shift and plan re‐optimization to account for setup discrepancy between simulation and treatment. For each adaptive session, CT–MR images were fused and isocenter translational shifts recorded. Differences among the three roles (Therapist, Physicist 1, Physicist 2) were assessed by repeated‐measures analysis of variance (RM‐ANOVA) and Bonferroni‐corrected post‐hoc paired t tests, reported as secondary, exploratory analyses. Agreement on shifts and dosimetric endpoints was quantified with Lin's concordance correlation coefficient (CCC), with bias‐corrected and accelerated bootstrap 95% confidence intervals (CIs), as the primary analysis. Results: No significant differences were observed among roles for X‐ or Y‐axis shifts ( p = 0.804 and p = 0.950). A statistically significant difference was observed for Z‐axis shifts ( p = 0.005), driven by Therapist versus Physicist 1 (Bonferroni‐adjusted p = 0.015; mean paired difference 0.10 cm, 95% CI 0.04–0.17 cm), a systematic difference of approximately 1 mm that is small relative to clinical planning margins. CCC point estimates were 0.866–0.970 for translational shifts and 0.972–0.997 for target coverage and maximum dose, with no point estimate in the poor‐agreement range (CCC < 0.80). Bootstrap 95% CIs were wide for the shifts, as expected at n = 10, but therapist–physicist agreement was comparable to physicist–physicist agreement for every endpoint, and CI lower bounds for the dosimetric endpoints were ≥0.75 (maximum dose ≥0.97). Conclusion: Our results showed good concordance between adaptive plans created by radiation therapists and medical physicists in the ATP workflow for head and neck cancer, suggesting that appropriately trained therapists can produce high‐quality adaptive plans in this specific context. These conclusions are limited to the ATP workflow and to head and neck cancer; extension to other sites or to the adapt‐to‐shape (ATS) workflow requires independent investigation.
- 24 October 2026
- Published by Wiley in Precision Radiation Oncology
Open AccessEvaluation of Concordance between Radiation Therapists and Medical Physicists in MR‐Guided Online Adaptive Planning
Purpose: Magnetic resonance (MR) ‐guided online adaptive radiotherapy requires skill in online adaptive treatment planning. The aim of this study was to demonstrate that radiation therapists, with appropriate training, can consistently produce high‐quality adaptive plans concordant with those created by medical physicists for treatment on a 1.5 Tesla MR‐Linac (MRL). Methods: We evaluated plans generated by two experienced MRL radiation therapists and two MR‐Linac medical physicists using an adapt‐to‐position (ATP) workflow to treat 10 patients with head and neck cancer; this workflow includes an iso‐center shift and plan re‐optimization to account for setup discrepancy between simulation and treatment. For each adaptive session, CT–MR images were fused and isocenter translational shifts recorded. Differences among the three roles (Therapist, Physicist 1, Physicist 2) were assessed by repeated‐measures analysis of variance (RM‐ANOVA) and Bonferroni‐corrected post‐hoc paired t tests, reported as secondary, exploratory analyses. Agreement on shifts and dosimetric endpoints was quantified with Lin's concordance correlation coefficient (CCC), with bias‐corrected and accelerated bootstrap 95% confidence intervals (CIs), as the primary analysis. Results: No significant differences were observed among roles for X‐ or Y‐axis shifts ( p = 0.804 and p = 0.950). A statistically significant difference was observed for Z‐axis shifts ( p = 0.005), driven by Therapist versus Physicist 1 (Bonferroni‐adjusted p = 0.015; mean paired difference 0.10 cm, 95% CI 0.04–0.17 cm), a systematic difference of approximately 1 mm that is small relative to clinical planning margins. CCC point estimates were 0.866–0.970 for translational shifts and 0.972–0.997 for target coverage and maximum dose, with no point estimate in the poor‐agreement range (CCC < 0.80). Bootstrap 95% CIs were wide for the shifts, as expected at n = 10, but therapist–physicist agreement was comparable to physicist–physicist agreement for every endpoint, and CI lower bounds for the dosimetric endpoints were ≥0.75 (maximum dose ≥0.97). Conclusion: Our results showed good concordance between adaptive plans created by radiation therapists and medical physicists in the ATP workflow for head and neck cancer, suggesting that appropriately trained therapists can produce high‐quality adaptive plans in this specific context. These conclusions are limited to the ATP workflow and to head and neck cancer; extension to other sites or to the adapt‐to‐shape (ATS) workflow requires independent investigation.
- 7 October 2026
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 82 (4)
Sample size determination for randomized decentralized clinical trials with longitudinal outcomes
Decentralized clinical trials (DCTs) offer significant advantages in enhancing trial accessibility, reducing patient burden, and improving population representativeness. These benefits are particularly pronounced in longitudinal trials, where patient outcomes are measured repeatedly over time. However, existing literature lacks appropriate sample size formulas tailored to longitudinal DCTs, which must account for heterogeneous measurement sources and increased uncertainty introduced by decentralized data collection. We propose a unified sample size calculation method for randomized longitudinal DCTs under the generalized linear model framework. The proposed formula is available in closed form and flexibly accommodates a variety of data collection designs, including the simple hybrid design, where all patients contribute both onsite and offsite data, and the stratified hybrid design, where different patient groups may undergo distinct data collection protocols. We also develop estimation procedures to estimate the unknown parameters and compute the sample statistics. Our method further generalizes to accommodate heterogeneous intraclass correlation coefficients, unequal variances between treatment arms, and varying numbers of data collection types or strata. Extensive simulation studies show that the proposed sample size formula achieves robust control of the type I error rate and maintains the desired power across a wide range of realistic scenarios.
- 7 October 2026
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 82 (4)
Sample size determination for randomized decentralized clinical trials with longitudinal outcomes
Decentralized clinical trials (DCTs) offer significant advantages in enhancing trial accessibility, reducing patient burden, and improving population representativeness. These benefits are particularly pronounced in longitudinal trials, where patient outcomes are measured repeatedly over time. However, existing literature lacks appropriate sample size formulas tailored to longitudinal DCTs, which must account for heterogeneous measurement sources and increased uncertainty introduced by decentralized data collection. We propose a unified sample size calculation method for randomized longitudinal DCTs under the generalized linear model framework. The proposed formula is available in closed form and flexibly accommodates a variety of data collection designs, including the simple hybrid design, where all patients contribute both onsite and offsite data, and the stratified hybrid design, where different patient groups may undergo distinct data collection protocols. We also develop estimation procedures to estimate the unknown parameters and compute the sample statistics. Our method further generalizes to accommodate heterogeneous intraclass correlation coefficients, unequal variances between treatment arms, and varying numbers of data collection types or strata. Extensive simulation studies show that the proposed sample size formula achieves robust control of the type I error rate and maintains the desired power across a wide range of realistic scenarios.
- 30 September 2026
- Published by Wiley in Pharmaceutical Statistics
- Vol. 25 (6) , e70120
TITE ‐ LOCRM12 : A Local Continual Reassessment Method for Drug Combination Optimization Based on Late‐Onset Toxicity and Efficacy Outcomes
The primary goal of Phase I/II combination trials is to identify the optimal biological dose combination (OBDC), defined as the dose combination that achieves the highest efficacy while maintaining an acceptable toxicity rate. Several designs have been proposed for such trials. Among them, the local continual reassessment method for Phase I/II trials (LOCRM12) performs well when compared with other model‐based methods in most of the scenarios studied. However, LOCRM12 assumes that both toxicity and efficacy outcomes are fully observed before enrolling the next cohort, an assumption that may not hold in real‐world settings, where late‐onset outcomes are increasingly common with the emergence of novel therapies such as molecularly targeted agents and immunotherapies. To address this limitation, we propose a time‐to‐event extension of LOCRM12 (TITE‐LOCRM12) that accommodates both late‐onset toxicity and efficacy outcomes. The local modeling framework, which uses data from neighboring dose combinations, is robust and efficient when data are sparse in complex combination settings. Simulation studies show that the proposed design can achieve a high percentage of correctly selecting the OBDC while maintaining a feasible trial duration.
- 30 September 2026
- Published by Wiley in Pharmaceutical Statistics
- Vol. 25 (6) , e70120
TITE ‐ LOCRM12 : A Local Continual Reassessment Method for Drug Combination Optimization Based on Late‐Onset Toxicity and Efficacy Outcomes
The primary goal of Phase I/II combination trials is to identify the optimal biological dose combination (OBDC), defined as the dose combination that achieves the highest efficacy while maintaining an acceptable toxicity rate. Several designs have been proposed for such trials. Among them, the local continual reassessment method for Phase I/II trials (LOCRM12) performs well when compared with other model‐based methods in most of the scenarios studied. However, LOCRM12 assumes that both toxicity and efficacy outcomes are fully observed before enrolling the next cohort, an assumption that may not hold in real‐world settings, where late‐onset outcomes are increasingly common with the emergence of novel therapies such as molecularly targeted agents and immunotherapies. To address this limitation, we propose a time‐to‐event extension of LOCRM12 (TITE‐LOCRM12) that accommodates both late‐onset toxicity and efficacy outcomes. The local modeling framework, which uses data from neighboring dose combinations, is robust and efficient when data are sparse in complex combination settings. Simulation studies show that the proposed design can achieve a high percentage of correctly selecting the OBDC while maintaining a feasible trial duration.
- Open Access
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Epidemiologic Characterization of Risk Factors in Patients with Dual Diagnosis of B-cell and T-cell Lymphomas
From the 2026 National Summit on Hematologic Cancers
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessEpidemiologic Characterization of Risk Factors in Patients with Dual Diagnosis of B-cell and T-cell Lymphomas
From the 2026 National Summit on Hematologic Cancers
- Open Access
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Survival Outcomes and Treatment Responses in Patients with Dual B-Cell and T-Cell Lymphoma Diagnoses
From the 2026 National Summit on Hematologic Cancers
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessSurvival Outcomes and Treatment Responses in Patients with Dual B-Cell and T-Cell Lymphoma Diagnoses
From the 2026 National Summit on Hematologic Cancers
- 3 August 2026
- Published by Taylor & Francis in Journal of the American Statistical Association
- p. 1-28
BAP: Bayesian Biomarker-Assisted Platform Design for Dose Ranging in Multi-Agent Multi-Dose Trials
1 IntroductionConventional clinical trials investigate new treatments one-at-a-time in a sequential manner. This strategy leads to a particularly long and costly drug development process that is we...
- 3 August 2026
- Published by Taylor & Francis in Journal of the American Statistical Association
- p. 1-28
BAP: Bayesian Biomarker-Assisted Platform Design for Dose Ranging in Multi-Agent Multi-Dose Trials
1 IntroductionConventional clinical trials investigate new treatments one-at-a-time in a sequential manner. This strategy leads to a particularly long and costly drug development process that is we...
- Open Access
- 1 August 2026
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 60 (5) , 1560-1564
Correction to: BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations
- 1 August 2026
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 60 (5) , 1560-1564
Open AccessCorrection to: BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection
Illustrative demonstration of the equivalence between a GPC utilizing a trade-off between DLT and preliminary response prioritizing DLTs (A) and a GPC first assessing DLTs and then preliminary response (B). Color coding indicates boxes with an equal number of wins between the two approaches to indicate their equivalence.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection
Illustrative demonstration of the equivalence between a GPC utilizing a trade-off between DLT and preliminary response prioritizing DLTs (A) and a GPC first assessing DLTs and then preliminary response (B). Color coding indicates boxes with an equal number of wins between the two approaches to indicate their equivalence.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection
Simulated data for illustrative case study.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection
Simulated data for illustrative case study.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection
Outcomes and endpoints (an exampe hierarchy) utilized to estimate the WR in this article.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection
Outcomes and endpoints (an exampe hierarchy) utilized to estimate the WR in this article.